Literature DB >> 26581989

Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.

Mary F Kearney1, Ann Wiegand2, Wei Shao3, John M Coffin4, John W Mellors5, Michael Lederman6, Rajesh T Gandhi7, Brandon F Keele3, Jonathan Z Li8.   

Abstract

UNLABELLED: Understanding the origin of HIV variants during viral rebound may provide insight into the composition of the HIV reservoir and has implications for the design of curative interventions. HIV single-genome sequences were obtained from 10 AIDS Clinical Trials Group participants who underwent analytic antiretroviral therapy (ART) interruption (ATI). Rebounding variants were compared with those in pre-ART plasma in all 10 participants and with on-ART peripheral blood mononuclear cell (PBMC)-associated DNA and RNA (CA-RNA) in 7/10 participants. The highest viral diversities were found in the DNA and CA-RNA populations. In 3 of 7 participants, we detected multiple, identical DNA and CA-RNA sequences during suppression on ART that exactly matched plasma HIV sequences. Hypermutated DNA and CA-RNA were detected in four participants, contributing to diversities in these compartments that were higher than in the pre-ART and post-ATI plasma. Shifts in the viral rebound populations could be detected in some participants over the 2- to 3-month observation period. These findings suggest that a source of initial rebound viremia could be populations of infected cells that clonally expanded prior to and/or during ART, some of which were already expressing HIV RNA before treatment was interrupted. These clonally expanding populations of HIV-infected cells may represent an important target for strategies aimed at achieving reservoir reduction and sustained virologic remission. IMPORTANCE: Antiretroviral therapy alone cannot eradicate the HIV reservoir, and viral rebound is generally rapid after treatment interruption. It has been suggested that clonal expansion of HIV-infected cells is an important mechanism of HIV reservoir persistence, but the contribution of these clonally proliferating cells to the rebounding virus is unknown. We report a study of AIDS Clinical Trials Group participants who underwent treatment interruption and compared rebounding plasma virus with that found within cells prior to treatment interruption. We found several incidences in which plasma HIV variants exactly matched that of multiple proviral DNA copies from infected blood cells sampled before treatment interruption. In addition, we found that these cells were not dormant but were generating unspliced RNA transcripts before treatment was interrupted. Identification of the HIV reservoir and determining its mechanisms for persistence may aid in the development of strategies toward a cure for HIV. (This study was presented in part at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23 to 26 2015.).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581989      PMCID: PMC4719635          DOI: 10.1128/JVI.02139-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  A robust measure of HIV-1 population turnover within chronically infected individuals.

Authors:  G Achaz; S Palmer; M Kearney; F Maldarelli; J W Mellors; J M Coffin; J Wakeley
Journal:  Mol Biol Evol       Date:  2004-06-23       Impact factor: 16.240

2.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

3.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

4.  Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.

Authors:  Jonathan Z Li; Andrea Heisey; Hayat Ahmed; Hongying Wang; Lu Zheng; Mary Carrington; Terri Wrin; Robert T Schooley; Michael M Lederman; Daniel R Kuritzkes
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

5.  Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.

Authors:  H Imamichi; K A Crandall; V Natarajan; M K Jiang; R L Dewar; S Berg; A Gaddam; M Bosche; J A Metcalf; R T Davey ; H C Lane
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

6.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

7.  Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

Authors:  Daniel J Skiest; Zhaohui Su; Diane V Havlir; Kevin R Robertson; Robert W Coombs; Pat Cain; Tianna Peterson; Amy Krambrink; Nasreen Jahed; Deborah McMahon; David M Margolis
Journal:  J Infect Dis       Date:  2007-04-06       Impact factor: 5.226

8.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

9.  HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Authors:  Frank Maldarelli; Mary Kearney; Sarah Palmer; Robert Stephens; JoAnn Mican; Michael A Polis; Richard T Davey; Joseph Kovacs; Wei Shao; Diane Rock-Kress; Julia A Metcalf; Catherine Rehm; Sarah E Greer; Daniel L Lucey; Kristen Danley; Harvey Alter; John W Mellors; John M Coffin
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

10.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

Authors:  Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors
Journal:  Clin Infect Dis       Date:  2014-07-29       Impact factor: 9.079

View more
  77 in total

1.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Authors:  Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho
Journal:  Cell Host Microbe       Date:  2017-04-12       Impact factor: 21.023

Review 3.  The Alphabet Soup of HIV Reservoir Markers.

Authors:  Radwa R Sharaf; Jonathan Z Li
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

4.  HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy.

Authors:  William R McManus; Michael J Bale; Jonathan Spindler; Ann Wiegand; Andrew Musick; Sean C Patro; Michele D Sobolewski; Victoria K Musick; Elizabeth M Anderson; Joshua C Cyktor; Elias K Halvas; Wei Shao; Daria Wells; Xiaolin Wu; Brandon F Keele; Jeffrey M Milush; Rebecca Hoh; John W Mellors; Stephen H Hughes; Steven G Deeks; John M Coffin; Mary F Kearney
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

5.  Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Authors:  Marta E Bull; Jennifer L McKernan; Sheila Styrchak; Kelli Kraft; Jane Hitti; Susan E Cohn; Kenneth Tapia; Wenjie Deng; Sarah Holte; James I Mullins; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-30       Impact factor: 2.205

Review 6.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

7.  Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.

Authors:  Antoine Chaillon; Sara Gianella; Steven M Lada; Josué Perez-Santiago; Parris Jordan; Caroline Ignacio; Maile Karris; Douglas D Richman; Sanjay R Mehta; Susan J Little; Joel O Wertheim; Davey M Smith
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

8.  Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors.

Authors:  Sean C Patro; Leah D Brandt; Michael J Bale; Elias K Halvas; Kevin W Joseph; Wei Shao; Xiaolin Wu; Shuang Guo; Ben Murrell; Ann Wiegand; Jonathan Spindler; Castle Raley; Christopher Hautman; Michele Sobolewski; Christine M Fennessey; Wei-Shau Hu; Brian Luke; Jenna M Hasson; Aurelie Niyongabo; Adam A Capoferri; Brandon F Keele; Jeff Milush; Rebecca Hoh; Steven G Deeks; Frank Maldarelli; Stephen H Hughes; John M Coffin; Jason W Rausch; John W Mellors; Mary F Kearney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-27       Impact factor: 11.205

9.  Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.

Authors:  Nathan W Cummins; Amy M Sainski-Nguyen; Sekar Natesampillai; Fatma Aboulnasr; Scott Kaufmann; Andrew D Badley
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

10.  Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Authors:  Mykola Pinkevych; Christine M Fennessey; Deborah Cromer; Martin Tolstrup; Ole S Søgaard; Thomas A Rasmussen; Brandon F Keele; Miles P Davenport
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.